{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:00:17Z","timestamp":1790002817472,"version":"4.0.1"},"reference-count":69,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jom-2026-0011_abs_001\">\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Rates of treatment-resistant hypertension in the United\u00a0States are increasing despite our better understanding of underlying mechanisms, lifestyle and pharmacologic approaches, and with refinement of treatment goals. Distinguishing treatment resistance from pseudo-resistance or even refractory hypertension is increasingly clinically difficult, and understanding the influences that dictate resistance in the primary care setting is needed to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2026-0011_abs_002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Herein, we will review current definitions of treatment resistance, pseudo-resistance, and refractory hypertension, and we will discuss patient- and provider-related factors that influence resistance, facilitating a more holistic approach to\u00a0care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2026-0011_abs_003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive narrative review utilizing PubMed as the basis for our medical literature search. We employed a combination of Medical Subject Headings (MeSH) terms and free-text keywords, including \u201ctreatment resistant hypertension,\u201d \u201cresistant hypertension,\u201d \u201crefractory hypertension,\u201d and \u201cpseudo-resistance.\u201d No language or date restrictions were applied for the initial search to help with wide capture of available literature that included a broad range of study designs, clinical guidelines, and consensus statements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2026-0011_abs_004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Resistance is classically defined as blood pressure (BP) &gt;130\/80\u202fmm Hg despite the use of three or more antihypertensives including a diuretic at optimized doses and with appropriate combination of drugs having complementary mechanisms of action, or with controlled BP requiring four or more anti-hypertensive drugs. Improper BP measurement techniques, underdosing antihypertensives, therapeutic inertia, nonadherence, and even a white coat effect contribute to pseudo-resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2026-0011_abs_005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Addressing factors that contribute to pseudo-resistance is of utmost significance in managing a patient with apparent treatment resistance or even refractory hypertension in the primary care setting. Recent strategies for managing true resistance include ambulatory BP monitoring or out-of-office home BP measurement, assessing underlying secondary causes, rational drug design to optimize the drug regimen, and a collaborative multidisciplinary approach with guidance from hypertension specialists. Addressing the factors that underlie pseudo-resistance and treatment resistance is consequential to improve not only major cardiovascular morbidity and mortality but also quality of life and tolerability of complex treatment regimens. Herein, we aim to address factors to improve care for hypertension in the primary care setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jom-2026-0011","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:02:59Z","timestamp":1789999379000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment-resistant hypertension in the primary care setting"],"prefix":"10.1515","author":[{"given":"Vijay","family":"Joshi","sequence":"first","affiliation":[{"name":"The Karl D. Nolph Division of Nephrology and Hypertension, University of Missouri School of Medicine, CE 414, 1 Hospital Drive , Columbia , MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreepriya","family":"Mangalgi","sequence":"additional","affiliation":[{"name":"Department of Medicine , The Karl D. Nolph Division of Nephrology and Hypertension, University of Missouri School of Medicine , Columbia , MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Medicine , The Karl D. Nolph Division of Nephrology and Hypertension, University of Missouri School of Medicine , Columbia , MO , USA"},{"name":"Harry S. Truman Memorial Veterans Hospital , Columbia , MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Whaley-Connell","sequence":"additional","affiliation":[{"name":"Department of Medicine , The Karl D. Nolph Division of Nephrology and Hypertension, University of Missouri School of Medicine , Columbia , MO , USA"},{"name":"Harry S. Truman Memorial Veterans Hospital , Columbia , MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026092113554021258_j_jom-2026-0011_ref_001","doi-asserted-by":"crossref","unstructured":"Charchar, FJ, Prestes, PR, Mills, C, Ching, SM, Neupane, D, Marques, FZ, et al.. Lifestyle management of hypertension: International society of hypertension position paper endorsed by the world hypertension league and European society of hypertension. J\u00a0Hypertens 2024;42:23\u201349. https:\/\/doi.org\/10.1097\/HJH.0000000000003563.","DOI":"10.1097\/HJH.0000000000003563"},{"key":"2026092113554021258_j_jom-2026-0011_ref_002","unstructured":"Fryar, CD, Kit, B, Carroll, MD, Afful, J. Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United\u00a0States, August 2021-August 2023. NCHS Data Brief 2024;511:CS354233."},{"key":"2026092113554021258_j_jom-2026-0011_ref_003","doi-asserted-by":"crossref","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201\u00a0population-representative studies with 104 million participants. Lancet 2021;398:957\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1.","DOI":"10.1016\/S0140-6736(21)01330-1"},{"key":"2026092113554021258_j_jom-2026-0011_ref_004","unstructured":"Hypertension. World Health Organization. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension. Published September 25, 2025."},{"key":"2026092113554021258_j_jom-2026-0011_ref_005","doi-asserted-by":"crossref","unstructured":"Buso, G, Agabiti-Rosei, C, Lemoli, M, Corvini, F, Muiesan, ML. The global burden of resistant hypertension and potential treatment options. Eur Cardiol 2024;19:e07. https:\/\/doi.org\/10.15420\/ecr.2023.51.","DOI":"10.15420\/ecr.2023.51"},{"key":"2026092113554021258_j_jom-2026-0011_ref_006","doi-asserted-by":"crossref","unstructured":"Whelton, PK, Carey, RM, Aronow, WS, Casey, DE, Collins, KJ, Dennison Himmelfarb, C, et al.. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines. Hypertens 2018;71:1269\u2013324. https:\/\/doi.org\/10.1161\/HYP.0000000000000066.","DOI":"10.1161\/HYP.0000000000000075"},{"key":"2026092113554021258_j_jom-2026-0011_ref_007","doi-asserted-by":"crossref","unstructured":"Jones, DW, Ferdinand, KC, Taler, SJ, Johnson, HM, Shimbo, D, Marwah, A, et al., Writing Committee Members*. AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. Hypertens 2025;82:e212-316. https:\/\/doi.org\/10.1161\/HYP.0000000000000249.","DOI":"10.1161\/HYP.0000000000000249"},{"key":"2026092113554021258_j_jom-2026-0011_ref_008","doi-asserted-by":"crossref","unstructured":"McEvoy, JW, McCarthy, CP, Bruno, RM, Brouwers, S, Canavan, MD, Ceconi, C, et al.. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45:3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"2026092113554021258_j_jom-2026-0011_ref_009","doi-asserted-by":"crossref","unstructured":"Unger, T, Borghi, C, Charchar, F, Khan, NA, Poulter, NR, Prabhakaran, D, et al.. International society of hypertension global hypertension practice guidelines. Hypertens. 2020;75:1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"2026092113554021258_j_jom-2026-0011_ref_010","doi-asserted-by":"crossref","unstructured":"Carey, RM, Calhoun, DA, Bakris, GL, Brook, RD, Daugherty, SL, Dennison-Himmelfarb, CR, et al.. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association. Hypertens 2018;72:e53\u201390. https:\/\/doi.org\/10.1161\/HYP.0000000000000084.","DOI":"10.1161\/HYP.0000000000000084"},{"key":"2026092113554021258_j_jom-2026-0011_ref_012","doi-asserted-by":"crossref","unstructured":"Roerecke, M, Kaczorowski, J, Myers, MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med 2019;179:351\u201362. https:\/\/doi.org\/10.1001\/jamainternmed.2018.6551.","DOI":"10.1001\/jamainternmed.2018.6551"},{"key":"2026092113554021258_j_jom-2026-0011_ref_013","doi-asserted-by":"crossref","unstructured":"Krist, AH, Davidson, KW, Mangione, CM, Cabana, M, Caughey, AB, Davis, EM, et al., US Preventive Services Task Force. Screening for hypertension in adults: US preventive services task force reaffirmation recommendation statement. JAMA 2021;325:1650\u20136. https:\/\/doi.org\/10.1001\/jama.2021.4987.","DOI":"10.1001\/jama.2021.4987"},{"key":"2026092113554021258_j_jom-2026-0011_ref_014","doi-asserted-by":"crossref","unstructured":"Townsend, RR. Out-of-office blood pressure monitoring: a comparison of ambulatory blood pressure monitoring and home (self) monitoring of blood pressure. Hypertens 2020;76:1667\u201373. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.14650.","DOI":"10.1161\/HYPERTENSIONAHA.120.14650"},{"key":"2026092113554021258_j_jom-2026-0011_ref_015","doi-asserted-by":"crossref","unstructured":"Lee, EM. When and how to use ambulatory blood pressure monitoring and home blood pressure monitoring for managing hypertension. Clin Hypertens 2024;30:10. https:\/\/doi.org\/10.1186\/s40885-024-00265-w.","DOI":"10.1186\/s40885-024-00265-w"},{"key":"2026092113554021258_j_jom-2026-0011_ref_016","doi-asserted-by":"crossref","unstructured":"Durand, H, Hayes, P, Morrissey, EC, Newell, J, Casey, M, Murphy, AW, et al.. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J\u00a0Hypertens 2017;35:2346\u201357. https:\/\/doi.org\/10.1097\/HJH.0000000000001502.","DOI":"10.1097\/HJH.0000000000001502"},{"key":"2026092113554021258_j_jom-2026-0011_ref_017","doi-asserted-by":"crossref","unstructured":"Gupta, P, Patel, P, \u0160trauch, B, Lai, FY, Akbarov, A, Mare\u0161ov\u00e1, V, et al.. Risk factors for nonadherence to antihypertensive treatment. Hypertens 2017;69:1113\u201320. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08729.","DOI":"10.1161\/HYPERTENSIONAHA.116.08729"},{"key":"2026092113554021258_j_jom-2026-0011_ref_018","doi-asserted-by":"crossref","unstructured":"Cooke, CE, Xing, S, Gale, SE, Peters, S. Initial non-adherence to antihypertensive medications in the United\u00a0States: a systematic literature review. J\u00a0Hum Hypertens 2022;36:3\u201313. https:\/\/doi.org\/10.1038\/s41371-021-00549-w.","DOI":"10.1038\/s41371-021-00549-w"},{"key":"2026092113554021258_j_jom-2026-0011_ref_019","doi-asserted-by":"crossref","unstructured":"Reddy, RV, Santoyo, KC, Guerra, D, Lamy, C, Hertelendy, A, Barengo, NC. Cost-related medication nonadherence in adults with hypertension in the USA: implications for healthcare quality. Int J Qual Health Care 2025;37:mzaf039. https:\/\/doi.org\/10.1093\/intqhc\/mzaf039.","DOI":"10.1093\/intqhc\/mzaf039"},{"key":"2026092113554021258_j_jom-2026-0011_ref_020","doi-asserted-by":"crossref","unstructured":"Ruzicka, M, Leenen, FHH, Ramsay, T, Bugeja, A, Edwards, C, McCormick, B, et al.. Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med 2019;179:1433\u20134. https:\/\/doi.org\/10.1001\/jamainternmed.2019.1455.","DOI":"10.1001\/jamainternmed.2019.1455"},{"key":"2026092113554021258_j_jom-2026-0011_ref_021","doi-asserted-by":"crossref","unstructured":"Ozemek, C, Tiwari, S, Sabbahi, A, Carbone, S, Lavie, CJ. Impact of therapeutic lifestyle changes in resistant hypertension. Prog Cardiovasc Dis 2020;63:4\u20139. https:\/\/doi.org\/10.1016\/j.pcad.2019.11.012.","DOI":"10.1016\/j.pcad.2019.11.012"},{"key":"2026092113554021258_j_jom-2026-0011_ref_022","unstructured":"DASH - Following DASH. NHLBI, NIH [Internet]. [cited 2026 Apr 15]. Available from: https:\/\/www.nhlbi.nih.gov\/health\/dash\/following-dash."},{"key":"2026092113554021258_j_jom-2026-0011_ref_023","doi-asserted-by":"crossref","unstructured":"Tom\u00e9-Carneiro, J, Visioli, F. Plant-based diets reduce blood pressure: a systematic review of recent evidence. Curr Hypertens Rep 2023;25:127\u201350. https:\/\/doi.org\/10.1007\/s11906-023-01243-7.","DOI":"10.1007\/s11906-023-01243-7"},{"key":"2026092113554021258_j_jom-2026-0011_ref_024","doi-asserted-by":"crossref","unstructured":"Roerecke, M, Kaczorowski, J, Tobe, SW, Gmel, G, Hasan, OSM, Rehm, J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2017;2:e108\u201320. https:\/\/doi.org\/10.1016\/S2468-2667(17)30003-8.","DOI":"10.1016\/S2468-2667(17)30003-8"},{"key":"2026092113554021258_j_jom-2026-0011_ref_025","doi-asserted-by":"crossref","unstructured":"Vitarello, JA, Fitzgerald, CJ, Cluett, JL, Juraschek, SP, Anderson, TS. Prevalence of medications that May raise blood pressure among adults with hypertension in the United\u00a0States. JAMA Intern Med 2022;182:90\u20133. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6819.","DOI":"10.1001\/jamainternmed.2021.6819"},{"key":"2026092113554021258_j_jom-2026-0011_ref_026","doi-asserted-by":"crossref","unstructured":"Schiffrin, EL, Fisher, NDL. Diagnosis and management of resistant hypertension. BMJ 2024;385:e079108. https:\/\/doi.org\/10.1136\/bmj-2023-079108.","DOI":"10.1136\/bmj-2023-079108"},{"key":"2026092113554021258_j_jom-2026-0011_ref_027","doi-asserted-by":"crossref","unstructured":"Cohen, JB, Brown, NJ, Brown, SA, Dent, S, Van Dorst, DCH, Herrmann, SM, et al.. Cancer therapy\u2013related hypertension: a scientific statement from the American heart association. Hypertension 2023;80. https:\/\/doi.org\/10.1161\/HYP.0000000000000224.","DOI":"10.1161\/HYP.0000000000000224"},{"key":"2026092113554021258_j_jom-2026-0011_ref_028","doi-asserted-by":"crossref","unstructured":"Chan, RJ, Helmeczi, W, Hiremath, SS. Revisiting resistant hypertension: a comprehensive review. Intern Med J 2023;53:1739\u201351. https:\/\/doi.org\/10.1111\/imj.16189.","DOI":"10.1111\/imj.16189"},{"key":"2026092113554021258_j_jom-2026-0011_ref_029","doi-asserted-by":"crossref","unstructured":"Myat, A, Redwood, SR, Qureshi, AC, Spertus, JA, Williams, B. Resistant hypertension. BMJ 2012;345:e7473. https:\/\/doi.org\/10.1136\/bmj.e7473.","DOI":"10.1136\/bmj.e7473"},{"key":"2026092113554021258_j_jom-2026-0011_ref_030","doi-asserted-by":"crossref","unstructured":"Brown, JM, Siddiqui, M, Calhoun, DA, Carey, RM, Hopkins, PN, Williams, GH, et al.. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med 2020;173:10\u201320. https:\/\/doi.org\/10.7326\/M20-0065.","DOI":"10.7326\/M20-0065"},{"key":"2026092113554021258_j_jom-2026-0011_ref_031","doi-asserted-by":"crossref","unstructured":"Shih, MC, Lavorgna, TR, Dogra, P, Hirner, CN, Payne, K. Things we Do for no ReasonTM: failing to consider primary aldosteronism in the initial evaluation of hypertension, hypertensive urgency, and hypertensive emergency. J\u00a0Hosp Med 2025;20:998\u20131001. https:\/\/doi.org\/10.1002\/jhm.70035.","DOI":"10.1002\/jhm.70035"},{"key":"2026092113554021258_j_jom-2026-0011_ref_032","doi-asserted-by":"crossref","unstructured":"Dudenbostel, T, Siddiqui, M, Oparil, S, Calhoun, DA. Refractory hypertension: a novel phenotype of antihypertensive treatment failure. Hypertens 2016;67:1085\u201392. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.06587.","DOI":"10.1161\/HYPERTENSIONAHA.116.06587"},{"key":"2026092113554021258_j_jom-2026-0011_ref_033","doi-asserted-by":"crossref","unstructured":"Champaneria, MK, Patel, RS, Oroszi, TL. When blood pressure refuses to budge: exploring the complexity of resistant hypertension. Front Cardiovasc Med 2023;10:1211199. https:\/\/doi.org\/10.3389\/fcvm.2023.1211199.","DOI":"10.3389\/fcvm.2023.1211199"},{"key":"2026092113554021258_j_jom-2026-0011_ref_034","doi-asserted-by":"crossref","unstructured":"Lee, CJ, Ihm, SH, Shin, DH, Jeong, JO, Kim, JH, Chun, KH, et al.. Spironolactone vs amiloride for resistant hypertension: a randomized clinical trial. JAMA 2025;333:2073\u201382. https:\/\/doi.org\/10.1001\/jama.2025.5129.","DOI":"10.1001\/jama.2025.5129"},{"key":"2026092113554021258_j_jom-2026-0011_ref_035","doi-asserted-by":"crossref","unstructured":"Williams, B, MacDonald, TM, Morant, S, Webb, DJ, Sever, P, McInnes, G, et al.. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3.","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"2026092113554021258_j_jom-2026-0011_ref_036","doi-asserted-by":"crossref","unstructured":"Wang, C, Xiong, B, Huang, J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ 2016;25:1021\u201330. https:\/\/doi.org\/10.1016\/j.hlc.2016.02.016.","DOI":"10.1016\/j.hlc.2016.02.016"},{"key":"2026092113554021258_j_jom-2026-0011_ref_037","doi-asserted-by":"crossref","unstructured":"Rossignol, P, Claggett, BL, Liu, J, Vardeny, O, Pitt, B, Zannad, F, et al.. Spironolactone and resistant hypertension in heart failure with preserved ejection fraction. Am J Hypertens 2018;31:407\u201314. https:\/\/doi.org\/10.1093\/ajh\/hpx210.","DOI":"10.1093\/ajh\/hpx210"},{"key":"2026092113554021258_j_jom-2026-0011_ref_038","doi-asserted-by":"crossref","unstructured":"Williams, B, MacDonald, TM, Morant, SV, Webb, DJ, Sever, P, McInnes, GT, et al.. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6:464\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(18)30071-8.","DOI":"10.1016\/S2213-8587(18)30071-8"},{"key":"2026092113554021258_j_jom-2026-0011_ref_039","doi-asserted-by":"crossref","unstructured":"Manolis, AA, Manolis, TA, Melita, H, Manolis, AS. Eplerenone versus spironolactone in resistant hypertension: an efficacy and\/or cost or just a men\u2019s issue? Curr Hypertens Rep 2019;21:22. https:\/\/doi.org\/10.1007\/s11906-019-0924-0.","DOI":"10.1007\/s11906-019-0924-0"},{"key":"2026092113554021258_j_jom-2026-0011_ref_040","doi-asserted-by":"crossref","unstructured":"Helmeczi, W, Hundemer, GL. Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors. Curr Opin Nephrol Hypertens 2025;34:241\u20136. https:\/\/doi.org\/10.1097\/MNH.0000000000001067.","DOI":"10.1097\/MNH.0000000000001067"},{"key":"2026092113554021258_j_jom-2026-0011_ref_041","doi-asserted-by":"crossref","unstructured":"Agarwal, R, Sinha, AD, Pappas, MK, Abraham, TN, Tegegne, GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant 2014;29:672\u201381. https:\/\/doi.org\/10.1093\/ndt\/gft515.","DOI":"10.1093\/ndt\/gft515"},{"key":"2026092113554021258_j_jom-2026-0011_ref_042","doi-asserted-by":"crossref","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981\u201397. https:\/\/doi.org\/10.1001\/jama.288.23.2981.","DOI":"10.1001\/jama.288.23.2981"},{"key":"2026092113554021258_j_jom-2026-0011_ref_043","doi-asserted-by":"crossref","unstructured":"Jackevicius, CA, Ghaznavi, Z, Lu, L, Warner, AL. Safety of alpha-adrenergic receptor antagonists in heart failure. JACC Heart Fail 2018;6:917\u201325. https:\/\/doi.org\/10.1016\/j.jchf.2018.06.015.","DOI":"10.1016\/j.jchf.2018.06.015"},{"key":"2026092113554021258_j_jom-2026-0011_ref_044","doi-asserted-by":"crossref","unstructured":"Jeong, JY, Kim, MK, Shin, JY. The association between alphablockers in the treatment of benign prostatic hyperplasia and heart failure: a nationwide population-based cohort study in South Korea. Int J Clin Pharmacol Ther 2025;63:21\u20139. https:\/\/doi.org\/10.5414\/CP204600.","DOI":"10.5414\/CP204600"},{"key":"2026092113554021258_j_jom-2026-0011_ref_045","doi-asserted-by":"crossref","unstructured":"Sousa, JP, Mendon\u00e7a, D, Teixeira, R, Gon\u00e7alves, L. Do adrenergic alpha-antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta-analysis. ESC Heart Fail 2022;9:2823\u201339. https:\/\/doi.org\/10.1002\/ehf2.14012.","DOI":"10.1002\/ehf2.14012"},{"key":"2026092113554021258_j_jom-2026-0011_ref_046","doi-asserted-by":"crossref","unstructured":"Flack, JM, Sica, DA, Bakris, G, Brown, AL, Ferdinand, KC, Grimm, RH, et al.. Management of high blood pressure in blacks: an update of the International society on hypertension in blacks consensus statement. Hypertens 2010;56:780\u2013800. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.152892.","DOI":"10.1161\/HYPERTENSIONAHA.110.152892"},{"key":"2026092113554021258_j_jom-2026-0011_ref_047","doi-asserted-by":"crossref","unstructured":"Wong, GW, Laugerotte, A, Wright, JM. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension. Cochrane Database Syst Rev 2015;26:2015. https:\/\/doi.org\/10.1002\/14651858.CD007449.pub2.","DOI":"10.1002\/14651858.CD007449.pub2"},{"key":"2026092113554021258_j_jom-2026-0011_ref_048","doi-asserted-by":"crossref","unstructured":"Sica, DA, Grubbs, R. Transdermal clonidine: therapeutic considerations. J\u00a0Clin Hypertens 2005;7:558\u201362. https:\/\/doi.org\/10.1111\/j.1524-6175.2005.04133.x.","DOI":"10.1111\/j.1524-6175.2005.04133.x"},{"key":"2026092113554021258_j_jom-2026-0011_ref_049","doi-asserted-by":"crossref","unstructured":"Sinha, AD, Agarwal, R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. Clin J Am Soc Nephrol 2019;14:757\u201364. https:\/\/doi.org\/10.2215\/CJN.04330418.","DOI":"10.2215\/CJN.04330418"},{"key":"2026092113554021258_j_jom-2026-0011_ref_050","doi-asserted-by":"crossref","unstructured":"Cohn, JN, McInnes, GT, Shepherd, AM. Direct-acting vasodilators. J\u00a0Clin Hypertens 2011;13:690\u20132. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00507.x.","DOI":"10.1111\/j.1751-7176.2011.00507.x"},{"key":"2026092113554021258_j_jom-2026-0011_ref_051","doi-asserted-by":"crossref","unstructured":"Agarwal, R, Pitt, B, Palmer, BF, Kovesdy, CP, Burgess, E, Filippatos, G, et al.. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J 2023;16:293\u2013302. https:\/\/doi.org\/10.1093\/ckj\/sfac234.","DOI":"10.1093\/ckj\/sfac234"},{"key":"2026092113554021258_j_jom-2026-0011_ref_052","doi-asserted-by":"crossref","unstructured":"Gadve, SS, Gadve, SS, Gadve, S, Chavanda, KS, Hanamshetti, S. 878-P: effect of finerenone on resistant hypertension in type 2 diabetes mellitus\u2014a randomized controlled trial in Indian population. Diabetes 2024;73:878\u2013P. https:\/\/doi.org\/10.2337\/db24-878-P.","DOI":"10.2337\/db24-878-P"},{"key":"2026092113554021258_j_jom-2026-0011_ref_053","doi-asserted-by":"crossref","unstructured":"Flack, JM, Azizi, M, Brown, JM, Dwyer, JP, Fronczek, J, Jones, ESW, et al.. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N\u00a0Engl J Med 2025;393:1363\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2507109.","DOI":"10.1056\/NEJMoa2507109"},{"key":"2026092113554021258_j_jom-2026-0011_ref_054","doi-asserted-by":"crossref","unstructured":"Zhang, Y, Huang, C, Liu, L, Wu, M, Song, H, Wan, S, et al.. Efficacy and safety of aldosterone synthase inhibitors for resistant hypertension: a systematic review and meta-analysis. Rev Cardiovasc Med 2025;26:39555. https:\/\/doi.org\/10.31083\/RCM39555.","DOI":"10.31083\/RCM39555"},{"key":"2026092113554021258_j_jom-2026-0011_ref_055","doi-asserted-by":"crossref","unstructured":"Khan, RS, Frishman, WH. Zilebesiran: a promising antihypertensive therapy inhibiting angiotensinogen synthesis. Cardiol Rev 2025;33:279\u201384. https:\/\/doi.org\/10.1097\/CRD.0000000000000645.","DOI":"10.1097\/CRD.0000000000000645"},{"key":"2026092113554021258_j_jom-2026-0011_ref_056","doi-asserted-by":"crossref","unstructured":"Zoccali, C, Mallamaci, F, De Nicola, L, Minutolo, R. New trials in resistant hypertension: mixed blessing stories. Clin Kidney J 2024;17:sfad251. https:\/\/doi.org\/10.1093\/ckj\/sfad251.","DOI":"10.1093\/ckj\/sfad251"},{"key":"2026092113554021258_j_jom-2026-0011_ref_057","doi-asserted-by":"crossref","unstructured":"Fisher, NDL, Kirtane, AJ. Renal denervation for hypertension. Nat Rev Cardiol 2025;22:664\u201374. https:\/\/doi.org\/10.1038\/s41569-024-01104-z.","DOI":"10.1038\/s41569-024-01104-z"},{"key":"2026092113554021258_j_jom-2026-0011_ref_058","doi-asserted-by":"crossref","unstructured":"Lauder, L, Azizi, M, Kirtane, AJ, B\u00f6hm, M, Mahfoud, F. Device-based therapies for arterial hypertension. Nat Rev Cardiol 2020;17:614\u201328. https:\/\/doi.org\/10.1038\/s41569-020-0364-1.","DOI":"10.1038\/s41569-020-0364-1"},{"key":"2026092113554021258_j_jom-2026-0011_ref_059","doi-asserted-by":"crossref","unstructured":"Tolu-Akinnawo, O, Ray, DN, Awosanya, T, Nzerue, C, Okafor, H. Hypertension and device-based therapies for resistant hypertension: an up-to-date review. Cureus 2024;16:e66304. https:\/\/doi.org\/10.7759\/cureus.66304.","DOI":"10.7759\/cureus.66304"},{"key":"2026092113554021258_j_jom-2026-0011_ref_060","doi-asserted-by":"crossref","unstructured":"Krum, H, Schlaich, M, Whitbourn, R, Sobotka, PA, Sadowski, J, Bartus, K, et al.. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(09)60566-3.","DOI":"10.1016\/S0140-6736(09)60566-3"},{"key":"2026092113554021258_j_jom-2026-0011_ref_061","doi-asserted-by":"crossref","unstructured":"Symplicity, HTN-2 I, Esler, MD, Krum, H, Sobotka, PA, Schlaich, MP, Schmieder, RE, et al.. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010;376:1903\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(10)62039-9.","DOI":"10.1016\/S0140-6736(10)62039-9"},{"key":"2026092113554021258_j_jom-2026-0011_ref_062","doi-asserted-by":"crossref","unstructured":"Bhatt, DL, Kandzari, DE, O\u2019Neill, WW, D\u2019Agostino, R, Flack, JM, Katzen, BT, et al.. A controlled trial of renal denervation for resistant hypertension. N\u00a0Engl J Med 2014;370:1393\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa1402670.","DOI":"10.1056\/NEJMoa1402670"},{"key":"2026092113554021258_j_jom-2026-0011_ref_063","doi-asserted-by":"crossref","unstructured":"Townsend, RR, Mahfoud, F, Kandzari, DE, Kario, K, Pocock, S, Weber, MA, et al.. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017;390:2160\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(17)32281-X.","DOI":"10.1016\/S0140-6736(17)32281-X"},{"key":"2026092113554021258_j_jom-2026-0011_ref_064","doi-asserted-by":"crossref","unstructured":"Kandzari, DE, B\u00f6hm, M, Mahfoud, F, Townsend, RR, Weber, MA, Pocock, S, et al.. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:2346\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(18)30951-6.","DOI":"10.1016\/S0140-6736(18)30951-6"},{"key":"2026092113554021258_j_jom-2026-0011_ref_065","doi-asserted-by":"crossref","unstructured":"Azizi, M, Schmieder, RE, Mahfoud, F, Weber, MA, Daemen, J, Davies, J, et al.. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391:2335\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(18)31082-1.","DOI":"10.1016\/S0140-6736(18)31082-1"},{"key":"2026092113554021258_j_jom-2026-0011_ref_066","doi-asserted-by":"crossref","unstructured":"Azizi, M, Sanghvi, K, Saxena, M, Gosse, P, Reilly, JP, Levy, T, et al.. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021;397:2476\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00788-1.","DOI":"10.1016\/S0140-6736(21)00788-1"},{"key":"2026092113554021258_j_jom-2026-0011_ref_067","unstructured":"Medtronic. GSR real-world registry - renal denervation [Internet]. https:\/\/europe.medtronic.com\/xd-en\/healthcare-professionals\/therapies-procedures\/cardiovascular\/renal-denervation\/clinical-data\/gsr-real-world-data.html [Accessed 18 Dec 2025]."},{"key":"2026092113554021258_j_jom-2026-0011_ref_068","doi-asserted-by":"crossref","unstructured":"Mahfoud, F, B\u00f6hm, M, Schmieder, R, Narkiewicz, K, Ewen, S, Ruilope, L, et al.. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global SYMPLICITY registry. Eur Heart J 2019;40:3474\u201382. https:\/\/doi.org\/10.1093\/eurheartj\/ehz118.","DOI":"10.1093\/eurheartj\/ehz118"},{"key":"2026092113554021258_j_jom-2026-0011_ref_069","doi-asserted-by":"crossref","unstructured":"Bahrainwala, JZ, Etemadi, A, Chang, TI. Kidney denervation: latest breakthroughs and insights. Clin J Am Soc Nephrol 2026;21:1258\u201368. https:\/\/doi.org\/10.2215\/CJN.0000000972.","DOI":"10.2215\/CJN.0000000972"},{"key":"2026092113554021258_j_jom-2026-0011_ref_070","doi-asserted-by":"crossref","unstructured":"Schmieder, R, Burnier, M, East, C, Tsioufis, K, Delaney, S. Renal denervation: a practical guide for health professionals managing hypertension. Intervent Cardiol 2023;18:e06. https:\/\/doi.org\/10.15420\/icr.2022.38.","DOI":"10.15420\/icr.2022.38"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jom-2026-0011\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jom-2026-0011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:03:37Z","timestamp":1789999417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jom-2026-0011\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":69,"alternative-id":["10.1515\/jom-2026-0011"],"URL":"https:\/\/doi.org\/10.1515\/jom-2026-0011","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}